# Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

> **NCT00451555** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 156 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** placebo
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT00451555
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04-11
- **Primary completion:** 2010-12-28
- **Final completion:** 2018-10-18
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2019-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451555, "Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00451555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*